AI-Generated Filing Summaries

Moleculin Biotech, Inc. announced enrollment of the 45th subject in its pivotal Phase 2B/3 MIRACLE trial evaluating AnnAraC for relapsed or refractory acute myeloid leukemia, triggering final preparations for interim data unblinding on track for mid-2026. This milestone represents a potentially defining inflection point for the Company.

Stryker Corporation updated on its cybersecurity incident first reported on March 11 and 12, 2026, stating the threat actor used a non-spreading malicious file with no ransomware or malware, and no malicious activity directed at customers, suppliers, vendors, or partners. Palo Alto Networks Unit 42 confirmed containment as of March 20, 2026, with ongoing restoration efforts and no determined material impact.

WeRide Inc. reported record unaudited FY2025 revenue of RMB684.6 million, up 89.6% year over year, and Q4 2025 revenue of RMB314.0 million, up 123.0% year over year, with gross profit margin stable at 30.2% and net loss narrowing 34.2% year over year to RMB1.7 billion. The board authorized a US$100 million share repurchase program effective March 23, 2026.

Talphera, Inc. issued a press release announcing fourth quarter and full year 2025 financial results, including Q4 net loss of $3.8 million ($0.06 per share), full year net loss of $14.3 million ($0.34 per share), and cash and investments of $20.4 million as of December 31, 2025. The company reported 50% enrollment in the NEPHRO CRRT study, closure of a $4.1 million financing tranche, and 2026 cash operating expenses guidance of $17-18 million excluding stock-based compensation.

ANKAM INC. entered into a non-binding Memorandum of Understanding (MOU) with TRUST & ETHIC CO., LTD. (T&E Global) on March 23, 2026, to establish a strategic partnership and framework for potential future acquisition of T&E Global’s parent company upon meeting performance metrics. The MOU involves related party Mr. Wang Wen Lung, President and CEO, who will recuse from approvals; the Board approved it as arm's-length and fair.

NovaBay Pharmaceuticals, Inc. announced its name change to Stablecoin Development Corporation and ticker symbol change from NBY to SDEV effective April 3, 2026, alongside an update on its SKY token holdings of 2.06 billion tokens (8.78% of total supply) and 26.6 million in cumulative staking rewards as of March 16, 2026. This reflects the company's strategic shift to an on-chain holding company following its January 2026 private placement raising $134 million.

Tripadvisor, Inc. entered into a Cooperation Agreement with Starboard Value LP on March 22, 2026, expanding its Board from eight to ten directors by immediately appointing Dhiren R. Fonseca and Andrew F. Cates, and agreeing to include two additional Starboard-recommended nominees in its slate for the 2026 Annual Meeting. The Company also adopted Amended and Restated Bylaws permitting stockholder actions by written consent and special meetings, enhancing shareholder rights.

Adecoagro S.A. issued a convening notice for its Annual General Meeting on April 15, 2026, at 11:00 a.m. CET in Luxembourg, with agenda items including approval of 2025 consolidated financial statements showing a USD 6,759,000 loss, declaration of USD 35 million dividend from share premium account, board discharge, director re-elections and compensation approvals, and auditor re-appointment. This enables shareholders to vote on financial approvals, capital distribution, and governance matters.

Navigator Holdings Ltd. announced the closing on March 23, 2026, of a secondary public offering by BW Group Limited of 8,000,000 shares of common stock at $17.50 per share, with the Company not receiving any proceeds. Concurrently, the Company repurchased 3,500,000 shares from the underwriters at the same price, funded by cash on hand.

Theravance Biopharma, Inc. reported strong FY 2025 financial performance, achieving net income of $105.9 million compared to a $56.4 million net loss in 2024, driven by one-time gains and milestone achievements. Total revenues reached $107.5 million, up 67% YoY from $64.4 million, primarily from Viatris collaboration revenue of $75.0 million (up 16%) reflecting YUPELRI net sales growth to $266.6 million (up 12% YoY, with 7% demand increase) and $32.5 million in licensing/milestone revenue including $25.0 million YUPELRI sales milestone and $7.5 million China approval. Key non-operating items included $75.1 million net gain from TRELEGY royalty sale to GSK for $225.0 million proceeds and $50.0 million TRELEGY milestone income. Operating loss narrowed to -$3.6 million amid stable R&D at $37.4 million (-1% YoY) and SG&A rise to $73.7 million (+6% YoY). Cash from operations surged to $238.5 million, boosting liquidity to $326.5 million in cash/investments. Balance sheet strengthened with $485.6 million total assets and $296.7 million equity. Forward-looking, post-2026 restructuring targets 60% operating expense cut to ~$44 million annually, focusing on YUPELRI commercialization amid strategic review for shareholder value.

Bitmine Immersion Technologies, Inc. disclosed crypto, cash, and moonshot holdings totaling $11.0 billion as of March 22, 2026, including 4,660,903 ETH tokens (3.86% of ETH supply), 196 BTC, $200 million in Beast Industries, $95 million in ORBS, and $1.1 billion cash. Staked ETH reached 3,142,643 tokens ($6.5 billion at $2,072 per ETH) as of March 23, 2026, with MAVAN staking solution on track for Q1 2026 launch.

Gladstone Commercial Corporation announced on March 20, 2026, that David Gladstone stepped down as CEO while remaining Chairman, with Arthur “Buzz” Cooper appointed as CEO in addition to his President role, John Sateri as CIO, Gary Gerson as Executive Vice President alongside CFO duties, and Ryan Carter as Executive Vice President. These changes implement a strategic succession plan separating Chairman and CEO roles for governance and continuity.

Gladstone Commercial Corporation announced on March 20, 2026, that David Gladstone stepped down as CEO while remaining Chairman, with Arthur “Buzz” Cooper appointed as CEO in addition to his President role, John Sateri as CIO, Gary Gerson as Executive Vice President alongside CFO duties, and Ryan Carter as Executive Vice President. These changes implement a strategic succession plan separating Chairman and CEO roles for governance and continuity.

Gladstone Commercial Corporation announced on March 20, 2026, that David Gladstone stepped down as CEO while remaining Chairman, with Arthur “Buzz” Cooper appointed as CEO in addition to his President role, John Sateri as CIO, Gary Gerson as Executive Vice President alongside CFO duties, and Ryan Carter as Executive Vice President. These changes implement a strategic succession plan separating Chairman and CEO roles for governance and continuity.

On March 20, 2026, the Board of Gladstone Land Corporation appointed John Sateri as Chief Investment Officer, effective immediately, and simultaneously as CIO of Gladstone Capital Corporation, Gladstone Commercial Corporation, Gladstone Investment Corporation, and Gladstone Management Corporation. Mr. Sateri receives no direct compensation from the Company, as all officers are employed by the Adviser.

On March 20, 2026, the Board of Gladstone Land Corporation appointed John Sateri as Chief Investment Officer, effective immediately, and simultaneously as CIO of Gladstone Capital Corporation, Gladstone Commercial Corporation, Gladstone Investment Corporation, and Gladstone Management Corporation. Mr. Sateri receives no direct compensation from the Company, as all officers are employed by the Adviser.

On March 20, 2026, the Board of Gladstone Land Corporation appointed John Sateri as Chief Investment Officer, effective immediately, and simultaneously as CIO of Gladstone Capital Corporation, Gladstone Commercial Corporation, Gladstone Investment Corporation, and Gladstone Management Corporation. Mr. Sateri receives no direct compensation from the Company, as all officers are employed by the Adviser.

MindWalk Holdings Corp. disclosed SEDI insider activity in Exhibit 99.1 for March 16-20, 2026, where Dirk M.H. Van Hyfte (Charmquark EEN) and Ingrid M.H. Brands (Charmquark TWEE) each acquired 30,000 common shares on the open market, totaling 60,000 shares for USD $73,238 at an average price of $1.2178 per share. Holdings increased to 1,858,365 shares each, a 3.98% O/S change, offering investors visibility into insider transactions.

Gladstone Investment Corporation announced that David Gladstone stepped down as CEO effective March 20, 2026, while remaining Chairman of the Board. The Board appointed David A.R. Dullum as CEO, John Sateri as CIO, and promoted Erika Highland to Executive Vice President immediately and President effective October 1, 2026.

Gladstone Investment Corporation announced that David Gladstone stepped down as CEO effective March 20, 2026, while remaining Chairman of the Board. The Board appointed David A.R. Dullum as CEO, John Sateri as CIO, and promoted Erika Highland to Executive Vice President immediately and President effective October 1, 2026.

Gladstone Investment Corporation announced that David Gladstone stepped down as CEO effective March 20, 2026, while remaining Chairman of the Board. The Board appointed David A.R. Dullum as CEO, John Sateri as CIO, and promoted Erika Highland to Executive Vice President immediately and President effective October 1, 2026.

Gladstone Investment Corporation announced that David Gladstone stepped down as CEO effective March 20, 2026, while remaining Chairman of the Board. The Board appointed David A.R. Dullum as CEO, John Sateri as CIO, and promoted Erika Highland to Executive Vice President immediately and President effective October 1, 2026.

Gladstone Capital Corporation announced that David Gladstone stepped down as CEO effective March 20, 2026, remaining as Chairman, with Robert Marcotte appointed as successor CEO. The Board also promoted Michael McQuigg to President effective October 1, 2026, appointed John Sateri as CIO effective immediately, and Andrew Ahlberg as Executive Vice President, as part of a strategic succession plan.

Novo Nordisk A/S reported transactions under its share repurchase programme initiated 4 February 2026, purchasing 1,270,000 B shares from 16-20 March 2026 for DKK 308,156,081. Cumulative repurchases total 7,847,992 B shares for DKK 2,091,696,255, with treasury holdings at 25,237,791 B shares (0.6% of 4,465,000,000 total shares).

Novo Nordisk A/S reported transactions under its share repurchase programme initiated 4 February 2026, purchasing 1,270,000 B shares from 16-20 March 2026 for DKK 308,156,081. Cumulative repurchases total 7,847,992 B shares for DKK 2,091,696,255, with treasury holdings at 25,237,791 B shares (0.6% of 4,465,000,000 total shares).

Bally's Corporation (BALY) reported total revenue of $2.44 billion for FY 2025 ending December 31, 2025, primarily from gaming and entertainment offerings across casinos, iGaming, sportsbook, and lottery operations. Despite revenue, the company posted a loss from operations of $277.7 million, driven by total operating costs and expenses of $2.71 billion, including $1.14 billion in general and administrative expenses, $293.1 million in depreciation and amortization, and $181.6 million in impairment charges. Net other expense was $340.3 million, mainly from $365.2 million interest expense net, leading to a pretax loss of $618.0 million. After a $47.6 million tax provision, net loss was $665.5 million, with $650.1 million attributable to Bally's, or $11 basic and diluted loss per share on 60.6 million shares. Balance sheet reflects $11.23 billion total assets, including $3.43 billion goodwill and $3.00 billion intangibles, against $8.69 billion liabilities, with long-term debt net at $4.46 billion. Cash flows showed operating use of $11.0 million, investing inflow of $1.84 billion net amid $2.12 billion acquisitions, and financing outflow of $1.14 billion including $416.2 million share repurchases. Key 2025 developments included mergers adding casinos, Intralot combination for 57.9% ownership, and Chicago/Bronx projects, positioning for growth despite losses and risks like regulation and competition.

FEMSA completed an accelerated share repurchase (ASR) of approximately 2.5 million ADSs at an average price of $104.41 per ADS for a total of USD $260 million, with final settlement on March 23 and 24, 2026. The Company entered a new ASR with a U.S. financial institution for up to USD $300 million in ADSs, with initial delivery of 591,774 ADSs in March 2026 and final settlement in Q2 2026.

Abbott Laboratories completed its acquisition of Exact Sciences Corporation on March 23, 2026, pursuant to the Merger Agreement dated November 19, 2025. Each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, and Exact Sciences became a direct, wholly owned subsidiary of Abbott.

Damora Therapeutics, Inc. appointed Jennifer Jarrett as President and Chief Executive Officer effective March 30, 2026, succeeding Sherwin Sattarzadeh who continues as COO, and appointed Michael Landsittel and Cameron Turtle as Class III directors effective March 23, 2026. Three directors resigned, Peter Harwin became Board Chair, and Garrett Winslow received a new offer letter as General Counsel.

Infinity Natural Resources, LLC closed a $550 million private offering of 7.625% senior notes due 2031 on March 20, 2026, pursuant to an Indenture with U.S. Bank Trust Company as trustee. The notes are senior unsecured obligations guaranteed by certain subsidiaries, with net proceeds of approximately $537.4 million to repay Credit Facility borrowings and for general corporate purposes.